Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Holding ACXP?
Track your performance easily

Acurx Pharmaceuticals (ACXP) Income Statement

122 Followers

Acurx Pharmaceuticals Income Statement

Last quarter (Q2 2024), Acurx Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Acurx Pharmaceuticals's net income was $-4.12M. See Acurx Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 16.73M$ 14.58M$ 12.09M$ 12.81M$ 4.60M$ 5.93M
Operating Income
$ -16.73M$ -14.58M$ -12.09M$ -12.81M$ -4.60M$ -5.93M
Net Non Operating Interest Income Expense
------
Other Income Expense
---$ -66.50K--
Pretax Income
$ -16.73M$ -14.58M$ -12.09M$ -12.75M$ -4.60M$ -5.93M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -16.73M$ -14.58M$ -12.09M$ -12.75M$ -4.60M$ -5.93M
Basic EPS
$ -1.16$ -1.15$ -1.12$ -1.49$ -0.74$ -1.24
Diluted EPS
$ -1.16$ -1.15$ -1.12$ -1.49$ -0.74$ -1.24
Basic Average Shares
$ 58.16M$ 12.67M$ 10.82M$ 8.54M$ 8.89M$ 7.50M
Diluted Average Shares
$ 58.16M$ 12.67M$ 10.82M$ 8.54M$ 8.89M$ 7.50M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 16.73M$ 14.58M$ 12.09M$ 12.81M$ 4.60M$ 5.93M
Net Income From Continuing And Discontinued Operation
$ -16.73M$ -14.58M$ -12.09M$ -12.75M$ -4.60M$ -5.93M
Normalized Income
$ -12.46M$ -11.52M-$ -10.12M$ -4.60M$ -5.93M
Interest Expense
------
EBIT
$ -16.73M$ -14.58M$ -12.09M$ -12.75M$ -4.60M$ -5.93M
EBITDA
$ -16.73M$ -14.58M$ -12.09M$ -12.75M$ -4.60M$ -5.93M
Currency in USD

Acurx Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis